Infectious Disease Diagnostics Market is expected to reach US$ 59,954.22 million by 2030

Publisher: The Insight Partners

Molecular-Based Diagnostic Techniques Segment Held Largest Share of Infectious Disease Diagnostics Market in 2022

The infectious disease diagnostics market is expected to grow from US$ 38,366.38 million in 2022 to US$ 59,954.22 million by 2030; it is anticipated to register a CAGR of 5.7% from 2022 to 2030. 

The infectious disease diagnostics market, by technology, is segmented into biosensor-based, immunodiagnostics, molecular-based diagnostic, clinical biology, and others. The market for the molecular-based diagnostic techniques segment is subsegmented into polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, next generation sequencing, DNA microarrays, and others. In 2022, the molecular-based diagnostic techniques segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest rate in the coming years. Polymerase Chain Reaction (PCR) is a method that uses primers, i.e., short DNA sequences, to pick the portion of the genome that is to be amplified. In this method, the temperature of the sample is repeatedly reduced and raised to help a DNA replication enzyme copy the target DNA sequence. The technique can generate a billion copies of the required sequence in just a few hours. The COVID-19 pandemic has increased the need for rapid and reliable detection systems, such as qPCR. Improving reimbursement and regulatory scenarios for next-generation sequencing and PCR-based diagnostic tests will prove beneficial for molecular diagnostics. Favorable funding scenarios for genomics research across the globe will provide lucrative growth opportunities for growth of the NGS and PCR applications. Thus, the development of cost-effective next-generation sequencing services and products for researchers contributes to the overall market expansion.

Infectious Disease Diagnostics Market, by Region, 2022 (%)

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPHE100001430

Source: The Insight Partners Analysis

The infectious disease diagnostics market for the immunodiagnostics segment is further segmented into enzyme-linked immunosorbent assay, western blotting analysis, and immunofluorescence assay. Immunodiagnostics is a technique of detection by using the ability of antibodies to bind to an antigen specifically. This is a powerful, sensitive, and specific technique to detect a wide range of targets and has applications in the fields of infectious diseases and autoimmune disease detection, cancer diagnostics, food safety, environment, etc. It involves the use of fluorescent, radiological, or color-forming probes and enzymes for the identification of antibodies that help enhance the targeting range and identify disease progression. Immunodiagnostics also uses various reagents, instruments, and software-based solutions for enzyme-linked immunosorbent assay, chemilumines0cence, radioimmunoassay, and rapid testing. There is an increase in incidences of infectious diseases, including HIV, hepatitis B, STI, and others, across the world owing to the rise in the geriatric population and changes in demographics & lifestyle, which are the major factors driving the growth of the immunodiagnostics segment. Also, technological advancement in diagnosis kits, assays, and analyzers and an increase in awareness of preventive health measures among patients and medical professionals further stimulate the demand for immunodiagnostic products, boosting the segment growth.

Further, other technological advancements, such as the development of next-generation immunodiagnostics platforms, are anticipated to fuel the market growth in the coming years. These advanced point-of-care testing (POCT) systems offer enhanced diagnostic facilities for sepsis, acute cardiac infractions, and other medical disorders with higher mortality rates.

Abbott Laboratories, Bruker Corp, Cardinal Health, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, AccuBioTech Co Ltd, ACON Laboratories, and DiaSorin SpA are among the key companies operating in the infectious disease diagnostics market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name.

The report segments the infectious disease diagnostics market as follows: 

The infectious disease diagnostics market, by product, is segmented into kits & reagents, instruments, and software & services. The infectious disease diagnostics market, by technology, is segmented into biosensor-based, immunodiagnostics, molecular-based diagnostic, clinical biology, and others. The market for the immunodiagnostics segment is further segmented into enzyme-linked immunosorbent assay, western blotting analysis, and immunofluorescence assay. The market for the molecular-based diagnostic techniques segment is further segmented into polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, next generation sequencing, DNA microarrays, and others. The infectious disease diagnostics market, by application type, is bifurcated into point-of-care testing and laboratory testing. The infectious disease diagnostics market, by testing type, is bifurcated into human testing and veterinary testing. The market for the human testing segment is further segmented into HIV, Hepatitis, HAIs, HPV, tuberculosis, influenza, and others. The infectious disease diagnostics market, by end user, is segmented into diagnostic laboratories, hospitals and clinics, research institutes, homecare settings, and others. Based on geography, the infectious disease diagnostics market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Us: The Insight Partners 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com